Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Forte Biosciences (FBRX) EBITDA (2016 - 2020)

Forte Biosciences (FBRX) has disclosed EBITDA for 5 consecutive years, with -$4.5 million as the latest value for Q4 2020.

  • Quarterly EBITDA rose 57.68% to -$4.5 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was -$54.5 million through Dec 2020, up 14.08% year-over-year, with the annual reading at -$14.4 million for FY2025, 59.54% up from the prior year.
  • EBITDA for Q4 2020 was -$4.5 million at Forte Biosciences, up from -$5.0 million in the prior quarter.
  • The five-year high for EBITDA was -$352000.0 in Q3 2018, with the low at -$34.8 million in Q2 2020.
  • Average EBITDA over 5 years is -$12.0 million, with a median of -$10.1 million recorded in 2017.
  • The sharpest move saw EBITDA surged 96.46% in 2018, then tumbled 5226.14% in 2019.
  • Over 5 years, EBITDA stood at -$8.4 million in 2016, then dropped by 28.78% to -$10.9 million in 2017, then plummeted by 80.37% to -$19.6 million in 2018, then skyrocketed by 45.85% to -$10.6 million in 2019, then skyrocketed by 57.68% to -$4.5 million in 2020.
  • According to Business Quant data, EBITDA over the past three periods came in at -$4.5 million, -$5.0 million, and -$34.8 million for Q4 2020, Q3 2020, and Q2 2020 respectively.